1. LLY will present diabetes treatment data at the ADA conference. 2. New weight management drug orforglipron is in Phase 3 trials. 3. Efsitora alfa demonstrates potential as a once-weekly insulin therapy. 4. Tirzepatide's effects on kidney metrics will be discussed. 5. Investor event scheduled to highlight LLY's cardiometabolic health portfolio.
The positive clinical trial results across several investigational drugs can attract more investors and boost LLY’s stock price. Historical precedent shows that announcements related to successful clinical trials lead to immediate upward price movements, as seen with pharmaceuticals like Novo Nordisk post-approval of GLP-1 receptor agonists.
The article discusses groundbreaking treatments that could expand LLY's market share and revenue potential in diabetes and obesity management. The presentation at the ADA conference could also lead to increased analyst interest and consumer awareness, thereby impacting stock valuations.
In the short term, presentation dates and investor events are immediate catalysts. Historically, significant news disclosures often lead to quick trades and price alterations, especially in biotech stocks where investor sentiment can shift rapidly.
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.
Lilly will also host an investor event to highlight the company's cardiometabolic health portfolio and discuss key presentations from the ADA Scientific Sessions. The event will be held on Sunday, June 22 at 6:30 p.m. CDT and will be accessible via a live webcast on the "Webcasts & Presentations" section of Lilly's investor website. A replay will be available on the website following the event.
Presentation Title: Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists—Can They Become Players?
Presentation Date & Time: Saturday, June 21, 8 to 9:30 a.m. CDT
Location: W375 A
Presenter: Julio Rosenstock, MD
Presentation Title: Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!
Presentation Date & Time: Sunday, June 22, 1:30 to 3 p.m. CDT
Location: W375 A
Presenters: Julio Rosenstock, MD; Richard M. Bergenstal, MD; Athena Philis-Tsimikas, MD; Thomas Blevins, MD; Chantal Mathieu, MD, PhD
Presentation Title: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 Weeks
Abstract Number: 103-OR
Presentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDT
Location: W185 A-D
Presenter: Dr. Hiddo L. Heerspink, PhD
Presentation Title: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of Obesity
Abstract Number: 2169-LB
Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT
Location: Poster Hall (Hall F1)
Presenter: Ansarullah, PhD
Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018.
Insulin efsitora alfa (efsitora) is an investigational once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration.
Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon.
Eloralintide is an investigational selective, long-acting amylin receptor agonist designed to mimic the effects of native amylin while potentially improving tolerability and quality of weight loss.
Bimagrumab is an investigational monoclonal antibody that blocks activin type II receptors, which may promote muscle growth and fat mass reduction.
Tirzepatide is a once-weekly dual GIP receptor and GLP-1 receptor agonist, approved by the U.S. FDA as Mounjaro for adults with type 2 diabetes and as Zepbound for adults with obesity.
Zepbound (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity or overweight. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products.
Warnings: Zepbound may cause tumors in the thyroid, including thyroid cancer. Serious side effects include severe stomach problems, kidney problems, gallbladder problems, inflammation of the pancreas, serious allergic reactions, and low blood sugar.
Common side effects: The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach pain, and tiredness.
Before using Zepbound, consult your healthcare provider about any pre-existing conditions and medications.
For more information, visit Lilly.com/zepbound.
Lilly is a medicine company turning science into healing to make life better for people around the world. We're committed to providing innovative clinical trials and ensuring medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news.
Trademarks and trade names referred to in this press release are owned by their respective companies. This press release contains forward-looking statements and reflects Lilly's current belief and expectations.